Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.
about
Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugatesSimple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines.Perorally active nanomicellar formulation of quercetin in the treatment of lung cancerChemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.Intact reducing glycan promotes the specific immune response to lacto-N-neotetraose-BSA neoglycoconjugates.Vaccines based on the cell surface carbohydrates of pathogenic bacteria.Synthesis and immunological studies of linear oligosaccharides of β-glucan as antigens for antifungal vaccine developmentPreparation of glycoconjugates by dialkyl squarate chemistry revisited.Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates.Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteinsDesigning a new antifungal glycoconjugate vaccine.Be squared: expanding the horizon of squaric acid-mediated conjugations.The immune response to group B streptococcus type III capsular polysaccharide is directed to the -Glc-GlcNAc-Gal- backbone epitope.An Overview of Structural Features of Antibacterial Glycoconjugate Vaccines That Influence Their Immunogenicity.Neoglycoconjugate of Tetrasaccharide Representing One Repeating Unit of the Streptococcus pneumoniae Type 14 Capsular Polysaccharide Induces the Production of Opsonizing IgG1 Antibodies and Possesses the Highest Protective Activity As Compared to HeA semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine.Conjugate Vaccines from Bacterial Antigens by Squaric Acid Chemistry: A Closer Look.Chemical Synthesis Elucidates the Immunological Importance of a Pyruvate Modification in the Capsular Polysaccharide of Streptococcus pneumoniae Serotype 4.Synthesis and immunological evaluation of protein conjugates of Neisseria meningitidis X capsular polysaccharide fragments.Facile preparation of fluorescent neoglycoproteins using p-nitrophenyl anthranilate as a heterobifunctional linker.Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease.Synthesis of two linear PADRE conjugates bearing a deca- or pentadecasaccharide B epitope as potential synthetic vaccines against Shigella flexneri serotype 2a infection.A Three Component Synthetic Vaccine Containing a β-Mannan T-Cell Peptide Epitope and a β-Glucan Dendritic Cell Ligand
P2860
Q33251442-5C55754E-8B46-42AD-8D31-5ACAF8EC6E96Q34214205-F5BCB2FC-BE69-4CF6-982B-3FF8D0C075F1Q35753059-A0EFFD3D-062F-4F63-9064-AD80C073BEA6Q35783024-CCB8971B-53DC-47CC-B240-4E83BE9E13EAQ35897201-CF92A945-7CFE-4101-BEAD-122D7C3CA481Q36128243-3CAF8987-2E98-4862-9446-D5B3EF885752Q36331649-30F2038B-A4FB-458F-9A10-CB516508D184Q36492952-7AE89071-2411-4B40-A3AF-CF93886D3A1DQ36842967-B1A5A2C9-F519-413A-8F72-DCDF0B7273E5Q36869958-1B82568B-E102-473E-B1D2-FB17B560B3C1Q36898518-D4841836-19BC-461D-A3CE-2F288EE4061EQ37120643-E784873D-5AF0-428F-B4D7-10F904AFCBEDQ38066728-76D5C3BD-B7C4-49D5-AD20-B5C1CCC726CEQ38123105-014FCD5F-6B56-477E-A86E-BBD083FF6104Q38331254-21BAF83E-63A7-437B-94E8-5211FCDF3BCDQ39093233-D9E711BE-2EF5-42A6-8F07-607785AD0A2EQ40167840-BABAF994-4D01-45D4-BD82-BDB413659811Q40302199-C582E68F-39C9-405A-A0EC-F7FF243C808BQ40338497-CCF7E8D8-5ACD-4B61-ABC8-166425935837Q41089407-41054246-C23E-40DA-8D64-DF96D96E4FEBQ41669855-3849A4D3-7BB3-47FC-88CF-97BAF947E6EAQ41791108-294FC19E-E822-428D-B427-BC17EB74A9DEQ44891342-826AFF06-A839-4C2A-A047-357098AB1EC5Q45237263-95FDE4F8-9D49-4CC4-A204-E5E505EB43CEQ58692952-8C04961E-8BB1-4974-9ADF-B74596CC6818
P2860
Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@ast
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@en
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@nl
type
label
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@ast
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@en
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@nl
prefLabel
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@ast
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@en
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@nl
P2093
P2860
P1476
Immunogenicity in a mouse mode ...... ysaccharide coupled to CRM197.
@en
P2093
Christopher Jones
Fatme Mawas
Johannes F G Vliegenthart
Johannis P Kamerling
Jutta Niggemann
Michael J Corbel
P2860
P304
P356
10.1128/IAI.70.9.5107-5114.2002
P407
P577
2002-09-01T00:00:00Z